CTU logo
TRIALS CO-ORDINATING CENTRE
LSHTM logo
IMPROVING HEALTH WORLDWIDE
HALT-IT logo

HALT IT TRIAL - Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double blind placebo controlled trial

ISRCTN11225767

Tranexamic acid for the treatment of significant traumatic brain injury: an international randomised, double blind placebo controlled trial

ISRCTN15088122

Lancet Protocol Review and introductory films

 

Tranexamic Acid for the Treatment of Postpartum Hemorrhage: an international randomised, double blind placebo controlled trial

ISRCTN76912190

WOMAN-ETAC Study - Effect of tranexamic acid on coagulation in a sample of participants in the WOMAN trial

A large randomised placebo controlled trial among trauma patients with, or at risk of, significant haemorrhage, of the effects of antifibrinolytic treatment on death and transfusion requirement

ISRCTN86750102

FINAL RESULTS PUBLISHED ON LANCET ONLINE 15 June 2010

Abstracts in Spanish - Hindi - Chinese - Japanese

STUDY of the effect of tranexamic acid on INTRACRANIAL BLEEDING among CRASH-2 trial participants

Published on Lancet online 24 March 2011

CRASH-2 SUBGROUP ANALYSIS: The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial, CRASH-2 Collaborators

Effect of consent rituals on mortality in emergency care research
Ian Roberts, David Prieto-Merino, Haleema Shakur, Iain Chalmers, Jon Nicholl

All available for free download on the CRASH-2 trial dedicated webpage

Published on PLOS ONE 5 May 2011

Cost-Effectiveness Analysis of Administering Tranexamic Acid to Bleeding Trauma Patients Using Evidence from the CRASH-2 Trial. Carla Guerriero, John Cairns, Pablo Perel, Haleema Shakur, Ian Roberts

Published on BMJ 1 July 2011

Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study. CRASH-2 collaborators (Intracranial bleeding study)

Published on BMJ 15 August 2012

Predicting early death in patients with traumatic bleeding: development and validation of prognostic model. Pablo Perel, David Prieto-Merino, Haleema Shakur, Tim Clayton, Fiona Lecky, Omar Bouamra, Rob Russell, Mark Faulkner, Ewout W Steyerberg, Ian Roberts

Bradykinin B2 Receptor Antagonist (Anatibant) in Neurotrauma:
A phase II randomised, double blind, placebo-controlled, dose finding, safety and tolerability trial of XY2405 as a treatment for traumatic brain injury

ISRCTN23625128

RESULTS

A large simple placebo controlled trial, among adults with head injury and impaired consciousness, of the effects of a 48-hour infusion of corticosteroids on death and neurological disability

ISRCTN74459797

CRASH Head Injury Prognostic Models

BMJ paper


Last updated 06 June 2014

*** PLEASE CONTACT US IF YOU NEED FURTHER INFORMATION ABOUT ANY OF OUR TRIALS ***